ConvaTec Group (LON:CTEC) Insider Purchases £113,000 in Stock

ConvaTec Group PLC (LON:CTEC) insider Tobias Hestler acquired 50,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was purchased at an average price of GBX 226 per share, for a total transaction of £113,000.

ConvaTec Group Stock Performance

LON CTEC opened at GBX 232.80 on Friday. The company has a debt-to-equity ratio of 121.83, a current ratio of 1.93 and a quick ratio of 0.96. ConvaTec Group PLC has a 1-year low of GBX 193 and a 1-year high of GBX 259.30. The firm has a market capitalization of £4.55 billion, a P/E ratio of 27.07, a P/E/G ratio of 0.93 and a beta of 0.77. The business’s 50-day simple moving average is GBX 212.78 and its 200-day simple moving average is GBX 220.93.

Wall Street Analysts Forecast Growth

CTEC has been the topic of a number of recent research reports. Royal Bank Of Canada reaffirmed an “outperform” rating and set a GBX 315 price target on shares of ConvaTec Group in a research report on Monday. Jefferies Financial Group reissued a “buy” rating and issued a GBX 300 target price on shares of ConvaTec Group in a research note on Wednesday. Berenberg Bank restated a “buy” rating and set a GBX 340 target price on shares of ConvaTec Group in a report on Tuesday, April 21st. JPMorgan Chase & Co. decreased their price target on shares of ConvaTec Group from GBX 307 to GBX 294 and set an “overweight” rating for the company in a research report on Friday, May 22nd. Finally, Peel Hunt reiterated an “add” rating and issued a GBX 270 price target on shares of ConvaTec Group in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of GBX 306.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.